Showing results (31-40 of 604) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|October 30, 2024
Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 YearsEline H Ploumen, Martijn J Oude Wolcherink, Rosaly A Buiten, et al.
Pharmacoeconomics - Open|September 22, 2024
Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from ThailandTanawan Kongmalai, Juthamas Prawjaeng, Phorntida Hadnorntun, et al.
Pharmacoeconomics - Open|September 21, 2024
Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off AnalysisZheng-Yi Zhou, Mark E Bensink, Nisha C Hazra, et al.
Pharmacoeconomics - Open|February 13, 2025
So Many Choices, So Little Value: Potential Savings from Selecting Cost-Effective Proton Pump InhibitorsHye-Young Kwon
Pharmacoeconomics - Open|February 20, 2025
Cost Effectiveness of Left Ventricular Assist Devices (LVADs) as Destination Therapy: A Systematic ReviewTuba Saygın Avşar, Louise Jackson, Pelham Barton, et al.
Pharmacoeconomics - Open|August 19, 2024
Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in SpainSergio Cedillo, Almudena González-Domínguez, Yoana Ivanova-Markova, et al.
Pharmacoeconomics - Open|January 16, 2023
The Cost-Effectiveness of a Dance and Yoga Intervention for Girls with Functional Abdominal Pain DisordersAnna Philipson, Anna Duberg, Lars Hagberg, et al.
Pharmacoeconomics - Open|November 7, 2019
Correction to: Benefit-Cost Analysis of the Danish Sun Safety Campaign 2007-2015: Cost Savings from Sunburn and Sunbed Use Reduction and Derived Skin Cancer Reductions 2007-2040 in the Danish PopulationBrian Køster, Maria K H Meyer, Jes Søgaard, et al.
Pharmacoeconomics - Open|July 22, 2021
Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer PerspectiveNan Qiao, Ralph Insinga, Thomas Burke, et al.
Pharmacoeconomics - Open|July 26, 2021
Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and SwedenI van Oostrum, T A Russell-Smith, M Jakobsson, et al.
Pageof 61